Unlocking the Oral Antiviral

Favipiravir 200 mg Tablets flu ®

DCGI Approval *
granted to

for use in
Mild to Moderate
COVID-19 in India

* For Restricted Emergency Use

 STRIKE EARLY.
STRIKE HARD.

Favipiravir 200 mg Tablets flu ®

Has regulatory approval in key countries

RUSSIA
JAPAN
Approved for
COVID-191 Approved for new or
emerging pandemic
influenza viral2

FRANCE

Approved for
resistant Influenza3
INDIA Regulatory approved for COVID-19
Regulatory approved for influenza viruses

First DCGI approval* to

RO VED Glenmark for Mild to Moderate
APP
COVID-19 treatment

* For Restricted Emergency Use

IT’S TIME TO FIGHT BACK
1. Trialsite News. Russia Ministry of Health Approves Avifavir (Favipiravir) for COVID-19 Patients-
Cuts Duration of Illness by over 50%. [Internet] 2020 Jun 01 [cited 2020 Jun 04].
2. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 2019, 32:176–186.
3. Khambholja K, Asudani D. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
[published online ahead of print, 2020 Apr 28]. Travel Med Infect Dis. 2020;101710.
 STRIKE EARLY.
STRIKE HARD.

Favipiravir 200 mg Tablets flu ®

Being further studied across the globe

Experimental use CHINA

USA
against COVID-191
Experimental use
against COVID-192,3

ITALY

Experimental use Currently under Evaluation

against COVID-193

More than 23 clinical studies with

Favipiravir for COVID-19
currently undergoing across the globe

IT’S TIME TO FIGHT BACK

1. Clinical Trials. Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19: NCT04358549.
[Internet] 2020 Apr 28 [cited 2020 Jun 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT04358549.
2. Cai Q, Yang M, Liu D, Chen J, Shu, D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study [published online ahead of
print, 2020 Mar 18]. Engineering. 2020;10.1016/j.eng.2020.03.007.
3. Wikipedia. COVID-19 drug development. [Internet] [cited 2020 Jun 04]. Available from: https://en.wikipedia.org/wiki/COVID-19_drug_development.
 STRIKE EARLY.
STRIKE HARD.

Favipiravir 200 mg Tablets flu ®

Dosage
Day 1 Day 2 to max 14 days

Total daily dose 1800 mg bid 800 mg bid

Morning 200 mg x 9 tabs 200 mg x 4 tabs Each day

Evening 200 mg x 9 tabs 200 mg x 4 tabs Each day

Caution
Contraindicated in patients with severe renal,
hepatic impairment, pregnant and lactating women

Should be used with caution in patients with

history of abnormalities in metabolism of uric acid
or having gout
Contraindicated in patients with history of
w w w.fabiflu.in
hypersensitivity to Favipiravir

IT’S TIME TO FIGHT BACK

blets
f 34 ta
Strip o
 STRIKE EARLY.
ABRIDGED PRESCRIBING INFORMATION:
STRIKE HARD.

Favipiravir 200 mg Tablets flu ®

Abbreviated Prescribing Information: Fabiflu®(Favipiravir Tablets 200 mg)

Active ingredient:Favipiravir 200 mg. Indication:For the treatment of adults in mild to moderate
COVID-19 disease under restricted emergency use. Dosage and Administration:The
recommended dosage of favipiravir for adults is 1800 mg orally twice daily on 1st day followed by
800 mg orally twice daily, up to maximum of 14 days. Contraindications: Women known or
suspected to be pregnant (Early embryonic deaths and teratogenicity have been observed in
animal studies), lactating women, severe renal and hepatic impairment.Hypersensitivity to the
active substances or to any of the excipients.Warnings: When administering favipiravir to women
of child-bearing potential, confirm a negative pregnancy test result before starting the treatment.
Explain fully the risks and instruct thoroughly to use most effective contraceptive methods with her

For the use only of registered medical practitioners or a hospital or a laboratory.

partner during and for 7 days after the end of the treatment. If pregnancy is suspected during the
treatment, instruct to discontinue the treatment immediately and to consult a doctor. Favipiravir is
distributed in sperm. When administering the drug to male patients, explain fully the risks and
instruct thoroughly to use most effective contraceptive methods in sexual intercourse during and
for 7 days after the end of the treatment (men must wear a condom). In addition, instruct not to
have sexual intercourse with pregnant women. Prior to the treatment, explain thoroughly the
efficacy and risks (including the risk of exposure to fetus) to patients or their family members and
written informed consent from each patient/ or his representative prior to administration of the
drug shall be obtained by the prescriber.Precautions:Caution in patients with history of
abnormalities in metabolism of uric acid or having Gout. Psychoneurotic symptoms such as
abnormal behavior after administration of anti-influenza virus agents including favipiravir have
been reported.Drug interactions:Favipiravir mostly metabolized by aldehyde oxidase (AO), and
partly metabolized by xanthine oxidase (XO). The drug inhibits AO and CYP2C8, but does not
induce CYP. Precautions for co-administration of Pyrazinamide, Repaglinide, Famciclovir,
Sulindac. Pregnancy & Lactation:Contraindicated in pregnantand lactating women. Adverse
Events: The major undesirable effects observed in clinical studies with favipiravir used at different
doses included:Increase of blood uric acid level, diarrhoea, decrease of neutrophil count, increase
of AST (SGOT), increase of ALT (SGPT), psychiatric symptoms. The following clinically significant
adverse reactions have been reported with other anti-influenza virus agents. Patients should be
carefully monitored, and if any abnormality is observed, the treatment should be discontinued and
appropriate measures should be taken: Shock, anaphylaxis, Pneumonia, Hepatitis fulminant,
Hepatic dysfunction, Jaundice, Toxic epidermal necrolysis (TEN), Oculo-muco-cutaneous
syndrome (Stevens-Johnson syndrome), Acute renal failure, White blood cell count decreased,
Neutrophil count decreased, Platelet count decreased.

®
AbPI Ref: Fabiflu /18-JUN-2020
For further product related query contact: Glenmark Pharmaceuticals Limited (GPL), Medical
Services, Corporate Enclave, B. D. Sawant Marg, Chakala, Andheri (E), Mumbai – 99.Email id:
globalcustomerservice@glenmarkpharma.com
For any Adverse event or Product Quality Complaint related to Glenmark marketed product
contact on globalcustomerservice@glenmarkpharma.com

Written informed consent from each patient/ or his representative

prior to administration of the drug shall be obtained by the prescriber
i.e. medical specialist ‘Informed Consent’ form provided in each pack,
and available with Glenmark representatives.